AlzeCure Pharma Dirección

Dirección controles de criterios 3/4

El CEO de AlzeCure Pharma es Martin Jönsson , nombrado en Jan 2020, tiene una permanencia de 4.83 años. compensación anual total es SEK2.48M, compuesta por 76.6% salario y 23.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.46% de las acciones de la empresa, por valor de €38.20K. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 3.5 años, respectivamente.

Información clave

Martin Jönsson

Chief Executive Officer (CEO)

SEK 2.5m

Compensación total

Porcentaje del salario del CEO	76.6%
Permanencia del CEO	4.8yrs
Participación del CEO	0.5%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Martin Jönsson en comparación con los beneficios de AlzeCure Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-SEK 36m
Jun 30 2024	n/a	n/a	-SEK 36m
Mar 31 2024	n/a	n/a	-SEK 37m
Dec 31 2023	SEK 2m	SEK 2m	-SEK 37m
Sep 30 2023	n/a	n/a	-SEK 38m
Jun 30 2023	n/a	n/a	-SEK 42m
Mar 31 2023	n/a	n/a	-SEK 53m
Dec 31 2022	SEK 2m	SEK 2m	-SEK 56m
Sep 30 2022	n/a	n/a	-SEK 68m
Jun 30 2022	n/a	n/a	-SEK 73m
Mar 31 2022	n/a	n/a	-SEK 67m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 78m
Sep 30 2021	n/a	n/a	-SEK 73m
Jun 30 2021	n/a	n/a	-SEK 78m
Mar 31 2021	n/a	n/a	-SEK 81m
Dec 31 2020	SEK 2m	SEK 1m	-SEK 71m

Compensación vs. Mercado: La compensación total de Martin($USD225.04K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD474.54K).

Compensación vs. Ingresos: La compensación de Martin ha aumentado mientras la empresa no es rentable.

CEO

Martin Jönsson (56 yo)

4.8yrs

Permanencia

SEK 2,475,000

Compensación

Mr. Martin Jönsson is the Chief Executive Officer of AlzeCure Pharma AB (publ) since January 8, 2020. Mr. Jönsson served in a senior position at Ferring Pharmaceuticals in the US, he was business area dire...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Jönsson	Chief Executive Officer	4.8yrs	SEK 2.48m	0.46% € 38.2k
Birgitta Lundvik	Chief Financial Officer	7.8yrs	sin datos	0.14% € 11.4k
Johan Sandin	Chief Scientific Officer	4.8yrs	SEK 1.28m	0.99% € 81.7k
Marta Storck	Chief Medical Officer & Head of Development	3.6yrs	sin datos	0.084% € 6.9k
Pontus Forsell	Head of Research & Discovery	7.8yrs	sin datos	1.03% € 84.7k

4.8yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AC6 se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Pollare	Chairman	7.8yrs	SEK 229.00k	1.7% € 140.1k
Jan Lundberg	Director	less than a year	sin datos	sin datos
Ragnar Linder	Independent Director	7.8yrs	SEK 115.00k	0.056% € 4.6k
John Harrison	Scientific Advisor	no data	sin datos	sin datos
Bengt Winblad	Scientific Advisor	no data	sin datos	sin datos
Peter Snyder	Scientific Advisor	no data	sin datos	sin datos
Henrik Zetterberg	Scientific Advisor	no data	sin datos	sin datos
Rolf Karlsten	Scientific Advisor	no data	sin datos	sin datos
Janet Hoogstraate	Independent Director	1.5yrs	SEK 73.00k	0.028% € 2.3k
Sven Ogren	Scientific Advisor	no data	sin datos	sin datos
Eva Lilienberg	Independent Director	3.5yrs	SEK 115.00k	0.0028% € 233.1

3.5yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: La junta directiva de AC6 se considera experimentada (3.5 años de antigüedad promedio).

AlzeCure Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Chief Executive Officer recently bought €16k worth of stock

Chief Executive Officer recently bought €16k worth of stock

AlzeCure Pharma AB (publ), Annual General Meeting, May 12, 2021

Recent updates

AlzeCure Pharma AB (publ) Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

AlzeCure Pharma AB (publ) to Report Q2, 2025 Results on Aug 26, 2025

AlzeCure Pharma AB (publ) Announces an Abstract with Preclinical Data on NeuroRestore ACD856 Demonstrating Its Anti-In-In-In-Class Drug Candidate for Alzheimer's Disease

AlzeCure Pharma AB (publ) Announces New Results from Alzecure's Pain Project TrkA- NAM Presented At the Pain Conference IASP 2024

New minor risk - Shareholder dilution

Alzecure Pharma AB (Publ) Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

New minor risk - Financial position

AlzeCure Pharma AB (publ) Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024

New major risk - Market cap size

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference

AlzeCure Pharma AB (publ) Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's

New major risk - Revenue and earnings growth

AlzeCure Pharma AB (publ) Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

AlzeCure Pharma AB (publ) Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain

AlzeCure Pharma AB (publ) Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD

AlzeCure Pharma AB (publ) Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856

Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference

AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference

AlzeCure Pharma AB (publ) Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference

AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024

New minor risk - Financial position

AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024

AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's

AlzeCure Pharma AB (Publ) Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders

Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Forecast to breakeven in 2025

Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440

AlzeCure Pharma AB (publ) Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

Alzecure Pharma AB (Publ) Gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's

AlzeCure Pharma AB (publ) Gets Late-Breaking Abstract on New Data with Alzheimer Project

Alzecure Pharma AB (Publ) Announces New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented At Alzheimer's Conference CTAD

Alzheimer Announces New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856

AlzeCure Pharma AB (publ) Announces New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856

AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022

AlzeCure's Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

AlzeCure Pharma AB Gets Abstract on New Clinical Study Data with NeuroRestore Accepted At the Alzheimer's Conference Aaic

AlzeCure Pharma AB (Publ) Announces Update on Clinical Phase I Study

AlzeCure Pharma AB (publ) Announces First Patient Included in its Phase II Clinical Trial in Neuropathic Pain with Non-Opioid ACD440

Alzecure Pharma AB (Publ)'s Abstract on Pain Project TrkA-NAM Accepted for Presentation At IASP 2022

AlzeCure Pharma AB (publ) Gets Approval to Start Phase II Clinical Trial with Non-Opioid Pain Project ACD440

AlzeCure Pharma AB (publ) Publishes New Data on Alzstatin from Alzheimer Conference

AlzeCure Publishes New Data on NeuroRestore and Acd856 from Alzheimer's Conference

Chief Executive Officer recently bought €16k worth of stock

Chief Executive Officer recently bought €16k worth of stock

Alzecure Pharma AB (Publ) Receives Positive Indicative Clinical Data with Acd856 in Development for Alzheimer's Disease

Alzecure Pharma AB (publ) Announces Moving Towards Phase IIa Clinical Trial with ACD440 Based on Guiding Response from the FDA

AlzeCure Pharma AB (publ) to Present Abstract at ECNP Conference on NeuroRestore Project's Potential in Depression

AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021

New 90-day low: €0.74

New 90-day low: €0.77

AlzeCure Pharma AB (publ), Annual General Meeting, May 12, 2021

AlzeCure Pharma AB (publ) Receives Approval to Start Clinical Phase I Trial with ACD856 in Alzheimer's Disease

Chief Executive Officer recently bought €92k worth of stock

Alzecure Gets Abstract on the Neurorestore Platform Against Alzheimer's Accepted for Poster Presentation At CTAD

AlzeCure Pharma AB Provides Scientific Update on Alzheimer's Disease and the Alzstatin Project Platform

New 90-day high - €1.07

AlzeCure Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 28, 2021

New 90-day high - €0.76

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo